ZX-29

• CAT Number: I016204
• CAS Number: 2254805-62-2
• Molecular Formula: C₂₃H₂₈ClN₇O₃S
• Molecular Weight: 518.03
• Purity: ≥95%
• Target: Apoptosis
• IUPAC Name: N-[2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide
• InChI: InChI=1S/C23H28ClN7O3S/c1-30-10-12-31(13-11-30)16-8-9-20(21(14-16)34-2)27-23-25-15-17(24)22(28-23)26-18-6-4-5-7-19(18)29-35(3,32)33/h4-9,14-15,29H,10-13H2,1-3H3,(H2,25,26,27,28)
• InChIKey: ATHZZWBANOJUOA-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4NS(=O)(=O)C)Cl)OC

ZX-29 (Cat No.:I016204) is a potent and selective ALK (anaplastic lymphoma kinase) inhibitor that exhibits anticancer properties. It inhibits ALK, including ALK L1196M and ALK G1202R mutations, with high potency. Notably, it does not show activity against EGFR. ZX-29 induces apoptosis in cancer cells by triggering endoplasmic reticulum stress and overcomes cell resistance caused by ALK mutations. It also induces protective autophagy and exhibits antitumor effects. Treatment with ZX-29 leads to a dose-dependent decrease in cell viability, arrests cells in the G1 phase, and inhibits colony formation. Additionally, ZX-29 downregulates p-ALK and its downstream signaling proteins, including p-Akt and p-STAT3. In animal studies, ZX-29 administration has shown the ability to suppress tumor growth in a mouse xenograft model.

Reference

[1]. Gou W, et al. ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation. Biochim Biophys Acta Mol Cell Res. 2020 Mar 26;1867(7):118712.